Dowpharma announces biologics peptide manufacture
Dowpharma, a business unit of The Dow Chemical Company, has developed new, cost effective manufacturing solutions for peptides using Dowpharma's suite of biologics technologies.
Dowpharma, a business unit of The Dow Chemical Company, has developed new, cost effective manufacturing solutions for peptides using Dowpharma's suite of biologics technologies.
Dowpharma's technology suite is particularly well suited for the manufacture of medium- to long-chain peptides (>20 AA residues). Dowpharma has a number of ongoing client projects that use recombinant technology for the production of peptides, and most recently The Dow Chemical Company and NOBEX Corporation announced a collaboration on the plant-based production of a proprietary peptide currently in preclinical development as a potential appetite suppressant to treat obesity.
'With many options at our fingertips, we can rapidly assess a client's peptide candidate and develop an efficient expression and purification strategy to produce a high quality product that addresses their cost of goods concerns,' said Nick Hyde, business director, Dowpharma. 'These additional tailored solutions are made possible through the recently expanded Dowpharma portfolio.'